In this discussion, panelists explore the potential role of new Bruton tyrosine kinase inhibitors in the treatment landscape for chronic spontaneous urticaria (CSU), evaluating their stages of development and expected impact on treatment algorithms, while also considering future changes in coverage and payer strategies with the emergence of new therapies.
Video content above is prompted by the following question:
a. Given the data you’ve seen to date, how would you advise managed
a. With potential new treatment options on the horizon, how do you think payers should anticipate covering CSU in the next few years?
Real-World Data Support Dual Benefit of Biologic Therapy for Hidradenitis Suppurativa
September 27th 2025The study confirms that biologics are highly effective in real-world HS management, and highlights the need for a comprehensive treatment strategy considering both skin symptoms and systemic health.
Read More
Real-World Data Support Dual Benefit of Biologic Therapy for Hidradenitis Suppurativa
September 27th 2025The study confirms that biologics are highly effective in real-world HS management, and highlights the need for a comprehensive treatment strategy considering both skin symptoms and systemic health.
Read More
2 Commerce Drive
Cranbury, NJ 08512